While the effect of statins on cognitive function in CKD remains unclear, the monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody evolocumab showed no impact on cognition in the Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects study, which included elderly individuals with an eGFR <60 ml/min/1.73 m2 [113], suggesting that more evidence is needed to confirm the benefits of this type of treatment in the cognitive domain. The gene discussed is PCSK9; the disease is chronic kidney disease.